Value
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.6 |
| P/S | 7.5 |
| EV/EBITDA | 3.1 |
| Fwd P/E | 8.3 |
| PEG | 4.8 |
| Analyst target | 7.5 |
- ▸Forward P/E: 14.1x
- ▸PEG: 1.73
GMAB · Why this verdict
Why Genmab A/S (GMAB) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A high-quality biotech franchise with 25% revenue growth, strong margins, and a risk/reward ratio of approximately 5-to-1 is navigating a phase of technical deterioration — including a death cross and two consecutive earnings misses — that represents a near-term headwind rather than a structural change, provided quality fundamentals remain intact.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With gross, operating, and net margins each scoring at or near the top of their ranges, a Rule of 40 score of 47, and a Piotroski F-Score of 7 out of 9, this is a high-quality business with durable profitability that supports a premium to most biotech peers. Quality | Quality holds if the Rule of 40 stays above 40 and trailing margins remain above 21% over the next 12 months. | →Stable |
| CounterThe two most recent quarterly results missed estimates by 30% and 45% respectively, signaling that revenue expansion may not be flowing to the bottom line at the expected rate and raising the question of whether the high margins can be maintained as the business scales. | ||
Revenue growing at 25% year over year and a peer-relative ranking that is superior across both quality and growth dimensions position the company to compound intrinsic value at an above-market rate and support a durable valuation premium. Growth | The growth thesis holds if revenue growth stays above 15% year over year for the next 2 quarters. | →Stable |
| CounterThe two most recent earnings prints missed estimates by wide margins, with the most recent miss of approximately 30% suggesting either that consensus estimates had moved well ahead of the underlying revenue trajectory or that cost pressures are absorbing a disproportionate share of the revenue gain. | ||
At a risk/reward ratio of approximately 5-to-1, with 30% upside to the analyst consensus target versus roughly 6% to the defined downside, the setup offers highly asymmetric reward for buyers willing to hold through near-term price weakness. Price targets | The thesis holds if the stock reaches the $32 take-profit level within 12 months; it weakens if analyst consensus targets are revised materially below $28. | →Stable |
| CounterWith falling On-Balance Volume and the stock sitting below all its moving averages in a death-cross formation, the near-term price path may move lower before any mean-reversion takes hold, eroding the effective entry-point advantage that the favorable ratio assumes. | ||
The stock currently sits below all its moving averages with an RSI near 35 and a bearish MACD crossover, but the 200-day moving average continues to slope upward at approximately 1.7% per month — signaling a pullback within an established uptrend rather than a confirmed trend reversal. Momentum | The pullback resolves if the stock crosses back above its 200-day moving average and momentum recovers above the minimum gate threshold within 2 quarters. | →Stable |
| CounterTwo consecutive earnings misses — the most recent two reporting quarters — could extend selling pressure well beyond a typical technical pullback and convert what appears to be a temporary dip into a deeper structural decline, particularly if the next print also disappoints. | ||
With gross, operating, and net margins each scoring at or near the top of their ranges, a Rule of 40 score of 47, and a Piotroski F-Score of 7 out of 9, this is a high-quality business with durable profitability that supports a premium to most biotech peers.
→StableQuality
- Expectation
- Quality holds if the Rule of 40 stays above 40 and trailing margins remain above 21% over the next 12 months.
CounterThe two most recent quarterly results missed estimates by 30% and 45% respectively, signaling that revenue expansion may not be flowing to the bottom line at the expected rate and raising the question of whether the high margins can be maintained as the business scales.
Revenue growing at 25% year over year and a peer-relative ranking that is superior across both quality and growth dimensions position the company to compound intrinsic value at an above-market rate and support a durable valuation premium.
→StableGrowth
- Expectation
- The growth thesis holds if revenue growth stays above 15% year over year for the next 2 quarters.
CounterThe two most recent earnings prints missed estimates by wide margins, with the most recent miss of approximately 30% suggesting either that consensus estimates had moved well ahead of the underlying revenue trajectory or that cost pressures are absorbing a disproportionate share of the revenue gain.
At a risk/reward ratio of approximately 5-to-1, with 30% upside to the analyst consensus target versus roughly 6% to the defined downside, the setup offers highly asymmetric reward for buyers willing to hold through near-term price weakness.
→StablePrice targets
- Expectation
- The thesis holds if the stock reaches the $32 take-profit level within 12 months; it weakens if analyst consensus targets are revised materially below $28.
CounterWith falling On-Balance Volume and the stock sitting below all its moving averages in a death-cross formation, the near-term price path may move lower before any mean-reversion takes hold, eroding the effective entry-point advantage that the favorable ratio assumes.
The stock currently sits below all its moving averages with an RSI near 35 and a bearish MACD crossover, but the 200-day moving average continues to slope upward at approximately 1.7% per month — signaling a pullback within an established uptrend rather than a confirmed trend reversal.
→StableMomentum
- Expectation
- The pullback resolves if the stock crosses back above its 200-day moving average and momentum recovers above the minimum gate threshold within 2 quarters.
CounterTwo consecutive earnings misses — the most recent two reporting quarters — could extend selling pressure well beyond a typical technical pullback and convert what appears to be a temporary dip into a deeper structural decline, particularly if the next print also disappoints.
Per-dimension breakdown
Quality
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.0 |
| ROA | 5.7 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 7.6 |
| FCF quality | 7.1 |
| Moat | 6.9 |
| Rule of 40 | 7.8 |
| Piotroski F | 7.8 |
- ▸Strong margins: 21%
- ▸Rule of 40: 47 (pass)
- ▸Strong Piotroski F-Score: 7/9
- ▸High-quality business
Growth
4.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.8 |
| EPS growth | 0.0 |
- ▸Strong growth: 25% YoY
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+1.0%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 8.3 |
| Price target | 9.2 |
- ▸LLM news sentiment: +0.60 (n=1)
- ▸Analyst upside: 40%
Insider
5.0/10data confidence 50%Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.1 |
| quality rank | 7.6 |
| growth rank | 5.3 |
- ▸Superior ROE vs peers
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 2.5 |
| 52w position | 4.8 |
Risk (lower is worse)
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.2 |
| days to cover | 6.0 |
| volatility | 6.3 |
| put call | 9.9 |
| implied vol | 0.2 |
| max pain risk | 3.0 |
| beta | 8.9 |
| debt equity | 5.3 |
- ▸High IV: 79%
- ▸Above max pain $15
Catalyst
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 6.2 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (8)
- MOMENTUM:5.7>=5.5
- ASYMMETRY:2.2>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.18
Upside
+22.0%
Downside
10.1%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 65
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.7>=5.5. Top dim: Sentiment at 8.5; weakest: Technical at 3.0. No conviction either direction.
The strongest dimensions are Sentiment at 8.5, Quality at 7.8, and Value at 6.4; the weakest are Technical at 3.0, Growth at 4.4, and Catalyst at 4.9. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.18 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With gross, operating, and net margins each scoring at or near the top of their ranges, a Rule of 40 score of 47, and a Piotroski F-Score of 7 out of 9, this is a high-quality business with durable profitability that supports a premium to most biotech peers.
Trip ifRule of 40 falls below 30 for 2 consecutive reporting periods, indicating that the combination of growth and margin has deteriorated materially from the current level of 47.
- P2Revenue growing at 25% year over year and a peer-relative ranking that is superior across both quality and growth dimensions position the company to compound intrinsic value at an above-market rate and support a durable valuation premium.
Trip ifRevenue growth falls below 10% year over year for 2 consecutive quarters, representing a deceleration of more than 15 percentage points from the current 25% rate.
- P3At a risk/reward ratio of approximately 5-to-1, with 30% upside to the analyst consensus target versus roughly 6% to the defined downside, the setup offers highly asymmetric reward for buyers willing to hold through near-term price weakness.
Trip ifAnalyst consensus price target is revised below $28, reducing upside to the take-profit level below 15% from the current price of $24.58.
- P4The stock currently sits below all its moving averages with an RSI near 35 and a bearish MACD crossover, but the 200-day moving average continues to slope upward at approximately 1.7% per month — signaling a pullback within an established uptrend rather than a confirmed trend reversal.
Trip ifThe 200-day moving average slope turns negative (below 0% per 30-day period) for 2 consecutive months, converting the pullback into a confirmed structural downtrend.